Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a little liver radiation boost cancer immunotherapy?

NCT ID NCT07225036

Recruiting now Disease control Sponsor: Jordan Kharofa Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether adding low-dose radiation to the liver before standard immunotherapy can help people with melanoma or non-small cell lung cancer that has spread to the liver. About 21 participants will receive radiation before their first three immunotherapy cycles. The goal is to see if this combination improves how long the cancer stays under control.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Low-dose radiation to the liver
What this could lead to
If it works, this could improve how well immunotherapy controls cancer in patients with liver metastases, potentially extending the time without disease progression.
What could go wrong
This is a very early, small trial with only 21 participants, so results may not apply broadly. The radiation could cause side effects like fatigue or liver irritation, and it may not improve outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LIVER METASTASES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

melanoma non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LIVER METASTASES LOW-DOSE LIVER RADIATION (LD-LRT) MELANOMA NON-SMALL CELL LUNG CANCER

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • University of Cincinnati Medical Center

    RECRUITING

    Cincinnati, Ohio, 45219, United States

    Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.